SMTI

Business Context and Reporting Period

Company: Wound Management Technologies, Inc. (WMT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2011
Business Overview: WMT operates primarily through its wholly-owned subsidiary, Wound Care Innovations, LLC (WCI), marketing the patented CellerateRX product for advanced wound care, specifically targeting diabetic wound applications. The company also holds a patent for resorbable orthopedic products. Manufacturing is outsourced to Applied Nutritionals, LLC. The company is classified as a "smaller reporting company" and a "shell company" is not applicable.

Key Financial Metrics

Note: The 2010 financial data has been restated to reflect the proper recording of derivative liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 143% to $2.21 million, driven by expanded distribution channels and a $500,000 upfront payment from a North American distribution agreement with Juventas, LLC.
• Net Loss Expansion: Net loss increased 92% to $12.74 million. This was primarily due to a $3.21 million impairment of intangible assets (marketing contacts) and a $4.38 million increase in debt-related expenses (non-cash warrant and conversion costs).
• Derivative Liabilities: Derivative liabilities increased from $2.31 million in 2010 to $5.42 million in 2011 due to the fair value adjustment of warrants and beneficial conversion features on convertible debt.
• Intangible Assets: Significant impairment of $3.21 million was recorded against marketing contacts acquired in the BioPharma acquisition, as minimum sales targets were not met.
• Debt Structure: The company utilized significant equity compensation (stock issuance) to secure financing and settle debt, resulting in substantial non-cash expenses.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The independent auditors issued a "going concern" qualification. The company has a working capital deficit and substantial accumulated deficit. Continued operations depend on raising additional capital, which is not guaranteed.
• Liquidity: Cash on hand was only $3,608 at year-end. The company expects to incur losses in the future and requires additional financing to fund operations and marketing.
• Management Changes: Subsequent to the reporting period (March 2012), Scott A. Haire resigned as CEO and Chairman, and Robert Lutz, Jr. was appointed to those roles. Deborah J. Hutchinson resigned as President.
• Legal Proceedings: Litigation was filed by Ken Link alleging default on a promissory note ($255,292 plus stock). The company disputes the claim, asserting usury and breach of contract by the plaintiff.
• Tax Liabilities: The company is delinquent on 2004-2005 payroll taxes. As of Dec 31, 2011, unpaid taxes were ~$116k with penalties/interest of ~$224k. A partial payment was made in Jan 2012, but negotiations for the remainder were ongoing.
• Concentration Risk: Two customers accounted for 69% of 2011 sales. The company relies on a single vendor (Applied Nutritionals) for all inventory.

Investor Verification Checklist

• Cash Runway: Verify current cash balances and any new financing secured post-filing, given the $3,608 cash balance and going concern warning.
• Debt Settlements: Review the terms of the $930,000 secured promissory note issued to Juventas in March 2012 following the termination of their distribution agreement.
• Intangible Asset Valuation: Assess the remaining value of the resorbable orthopedic patent and the likelihood of future revenue from the bone wax product line.
• Tax Resolution: Confirm the final settlement amount and status of the IRS payroll tax lien and penalties.
• Related Party Transactions: Scrutinize the ongoing financial relationships with H.E.B., LLC (managed by the CFO) regarding office leases, administrative services, and debt conversions.
• Stock Dilution: Monitor the impact of outstanding warrants (8.9 million) and convertible notes on future share count and dilution.